Skip to content
10-Q

Quarterly Report

VYNE THERAPEUTICS INC. VYNE

0001628280-25-023740

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 16.66M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $22.06M
Short Term Investments Q1 2025 · Dec 31, 2024 $41.59M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $28.21M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $19.93M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $19.07M
Current Liabilities Q1 2025 · Mar 31, 2025 $12.29M
Current Liabilities Q1 2025 · Dec 31, 2024 $14.82M
Total Liabilities Q1 2025 · Mar 31, 2025 $12.29M
Total Liabilities Q1 2025 · Dec 31, 2024 $14.82M
Current Assets Q1 2025 · Mar 31, 2025 $54.91M
Current Assets Q1 2025 · Dec 31, 2024 $64.44M
Total Assets Q1 2025 · Mar 31, 2025 $56.42M
Total Assets Q1 2025 · Dec 31, 2024 $66.91M
Shares Diluted Q1 2025 · Mar 31, 2024 42.58M sh
Operating Cash Flow restated Q1 2025 · Mar 31, 2024 −$7.98M
Stockholders Equity Q1 2025 · Mar 31, 2024 $83.37M
Stockholders Equity Q1 2025 · Dec 31, 2023 $88.74M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.15
Eps Basic Q1 2025 · Mar 31, 2024 −$0.15
Rd Expense Q1 2025 · Mar 31, 2024 $3.71M
Net Income Q1 2025 · Mar 31, 2024 −$6.25M
Operating Income Q1 2025 · Mar 31, 2024 −$7.38M
Revenue Q1 2025 · Mar 31, 2024 $98K